Xin Tao

Jun 4, 2024 | sanctionsnews.bakermckenzie.com | Janet Kim |Kerry Contini |Daniel Andreeff |Xin Tao

Bipartisan legislation advancing in the U.S. Senate and the U.S. House of Representatives known as the “BIOSECURE Act” (“the Act”) has the potential to significantly restrict the ability of biotechnology companies to collaborate with certain Chinese companies without losing the ability to contract with the U.S. government.

May 21, 2024 | mdpi.com | Xin Tao |Ruoyu ZHANG |Yuqing Zhang |Yu Wang

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Nov 14, 2023 | globalcompliancenews.com | Xin Tao

In briefIn the first three parts of this series (Part I, Part II and Part III), we provided an overview of the new US Food and Drug Administration (FDA) regulatory requirements under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), the good manufacturing practices (GMPs) regulations FDA plans to establish, as well as the FDA draft guidance on the facility registrations and products listings.

Nov 9, 2023 | lexology.com | Xin Tao

In briefFor quick background, under MoCRA, every person that, on December 29, 2022, owns or operates a facility that engages in the manufacturing or processing of a cosmetic product for distribution in the United States must register each facility no later than December 29, 2023. Further, the responsible person of a cosmetic product that is marketed on December 29, 2022, must submit a cosmetic product listing not later than December 29, 2023.

Aug 29, 2023 | globalcompliancenews.com | Xin Tao

In briefIn the first two parts of this series (Part I and Part II), we provided an overview of the new US Food and Drug Administration (FDA) regulatory requirements under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) and the good manufacturing practices (GMPs) regulations FDA plans to establish. In Part III, we will review the new FDA draft guidance on the facility registrations and products listings as mandated by MoCRA.